Cargando…

Exosomes as mediators of platinum resistance in ovarian cancer

Exosomes have been implicated in the cell-cell transfer of oncogenic proteins and genetic material. We speculated this may be one mechanism by which an intrinsically platinum-resistant population of epithelial ovarian cancer (EOC) cells imparts its influence on surrounding tumor cells. To explore th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crow, Jennifer, Atay, Safinur, Banskota, Samagya, Artale, Brittany, Schmitt, Sarah, Godwin, Andrew K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355315/ https://www.ncbi.nlm.nih.gov/pubmed/28060758 http://dx.doi.org/10.18632/oncotarget.14440

Ejemplares similares

Tumor-derived exosomes: A message delivery system for tumor progression
por: Atay, Safinur, et al.
Publicado: (2014)

Epimorphin-Induced MET Sensitizes Ovarian Cancer Cells to Platinum
por: Yew, Kok-Hooi, et al.
Publicado: (2013)

Correction: Epimorphin-Induced MET Sensitizes Ovarian Cancer Cells to Platinum
por: Yew, Kok-Hooi, et al.
Publicado: (2013)

Ewing sarcoma family of tumors-derived small extracellular vesicle proteomics identify potential clinical biomarkers
por: Samuel, Glenson, et al.
Publicado: (2020)

Decitabine reactivated pathways in platinum resistant ovarian cancer
por: Fang, Fang, et al.
Publicado: (2014)

Altered glutamine metabolism in platinum resistant ovarian cancer
por: Hudson, Chantelle D., et al.
Publicado: (2016)

Integrated immunoisolation and protein analysis of circulating exosomes using microfluidic technology
por: He, Mei, et al.
Publicado: (2014)

Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer
por: Matassa, D S, et al.
Publicado: (2016)

Resistance to glucose starvation as metabolic trait of platinum-resistant human epithelial ovarian cancer cells
por: Pastò, Anna, et al.
Publicado: (2016)

ATR Inhibitors in Platinum-Resistant Ovarian Cancer
por: Li, Siyu, et al.
Publicado: (2022)

Ovarian Cancer—Insights into Platinum Resistance and Overcoming It
por: Havasi, Andrei, et al.
Publicado: (2023)

Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
por: Gonzalez-Ochoa, Eduardo, et al.
Publicado: (2023)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Platinum resistance in breast and ovarian cancer cell lines
por: Eckstein, Niels
Publicado: (2011)

Platinum Resistance in Ovarian Cancer: Role of DNA Repair
por: Damia, Giovanna, et al.
Publicado: (2019)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer
por: Indini, Alice, et al.
Publicado: (2021)

Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer
por: Sassu, Carolina Maria, et al.
Publicado: (2021)

Ovarian cancer resistance to PARPi and platinum-containing chemotherapy
por: Summey, Rebekah, et al.
Publicado: (2022)

Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer
por: Flynn, Michael J., et al.
Publicado: (2022)

Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance
por: Nagaraj, Anil Belur, et al.
Publicado: (2015)

Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.
por: Jones, M., et al.
Publicado: (1993)

Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma
por: Sung, Pi-Lin, et al.
Publicado: (2015)

Markers of Oxidative Stress and Inflammation in Ascites and Plasma in Patients with Platinum-Sensitive, Platinum-Resistant, and Platinum-Refractory Epithelial Ovarian Cancer
por: Cantón-Romero, Juan Carlos, et al.
Publicado: (2017)

ADAM17 inhibition enhances platinum efficiency in ovarian cancer
por: Hedemann, Nina, et al.
Publicado: (2018)

Platinum-Taxol non-cross resistance in epithelial ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1995)

Oral melphalan as a treatment for platinum-resistant ovarian cancer
por: Hasan, J, et al.
Publicado: (2003)

Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
por: Pujade-Lauraine, Eric
Publicado: (2013)

A metabolomic approach to identifying platinum resistance in ovarian cancer
por: Poisson, Laila M, et al.
Publicado: (2015)

Prediction of Key Candidate Genes for Platinum Resistance in Ovarian Cancer
por: Guo, Kaidi, et al.
Publicado: (2021)

Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer
por: Yang, Ling, et al.
Publicado: (2022)

COPS5 Conferred the Platinum Resistance in Epithelial Ovarian Cancer
por: Zhang, Hongqin, et al.
Publicado: (2022)

Immunotherapy in the Treatment of Platinum-Resistant Ovarian Cancer: Current Perspectives
por: Awada, Ahmad, et al.
Publicado: (2022)

Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer
por: Nara, Katsuhiko, et al.
Publicado: (2023)

Overcoming the challenges of drug development in platinum-resistant ovarian cancer
por: Eskander, Ramez N., et al.
Publicado: (2023)

A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
por: Cui, Qingli, et al.
Publicado: (2021)

New Platinum(II) Complexes Affecting Different Biomolecular Targets in Resistant Ovarian Carcinoma Cells
por: Hyeraci, Mariafrancesca, et al.
Publicado: (2021)

Surgery in platinum-resistant recurrent epithelial ovarian carcinoma
por: Zhao, Ling-Qin, et al.
Publicado: (2022)

Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
por: Affatato, Roberta, et al.
Publicado: (2022)

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
por: Walsh, Christine S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4u7n2ji890keonbau2oaab9r7m